Catalyst overview
Research summary
This catalyst tracks a Failed discontinued for SION-719 in Cystic fibrosis . The expected timing is based on the latest available company guidance and may change.
6/4/25- Reported Ph1 data. Planned advancement to Ph2a proof-of-concept trial. 10/21/25- Trial initiated. 10/24/25– PK data reported; additional readout in mid-2026. 03/02/26:- PreciSION CF Ph2a POC trial ongoing; topline data still expected in Mid-2026. 04/27/26:- Completed enrollment in PreciSION CF Ph2a POC (NCT07108153). Data expected Summer 2026. 05/12/26:- Enrollment completed in PreciSION CF Ph2a POC; topline data still expected summer 2026. Encore Ph1 data at ECFS. 08/06/26:- PreciSION CF Ph2a POC topline data remain on track for Summer 2026. 08/10/26:- PreciSION CF Ph2a POC missed sweat chloride endpoint; SION-719 not advancing as add-on.
Verification
Confirm timing and program details against the company announcement or filing.